InflammaSense Named Performer on ARPA-H's up to $38 Million CIRCLE Award to Advance Real-Time Immune Monitoring in Critical Care
Original HTML
Company will measure autonomic and inflammatory signatures in up to 200 critically ill patients using its VITALx-patch wearable sensor and ARC cascade-endotyping classifier
LA JOLLA, Calif., Oct. 7, 2026 /PRNewswire/ -- InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, today announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program receiving up to $38M to transform how clinicians track and treat critical illness in intensive care units. InflammaSense joins the program as a subaward performer under prime awardee the University of Vermont, working alongside UVM's Gary An on the ReSCUED effort within CIRCLE.
ARPA-H's CIRCLE program, short for Critical Illness Immunological Reprogramming and Control Point Learning Engine, targets the immune dysregulation that drives organ failure in critically ill patients; sepsis accounts for a substantial share of the roughly 4.6 million Americans who face potentially fatal critical illness each year. The program follows a measure-model-modulate framework: compiling real-time datasets on immune and inflammatory trajectories, building patient-specific computational models, and testing interventions that target immune control points before organ failure progresses.
Under the subaward, InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 severely critically ill patients across three clinical sites. Data will feed the company's Autonomic Research Core (ARC) cascade-endotyping classifier, which stratifies patients by immune trajectory and supports the CIRCLE program's digital-twin modeling of critical illness. The work builds on InflammaSense's core platform; it was built on UC San Diego-owned intellectual property covering neural signal detection of immune responses through cervical Autonomic Neurography or "ANG" measured with ventral cervical or anterior neck magnetoneurography and electroneurography.
"CIRCLE gives us a path to validate ANG at scale in the population it was designed to serve," said Imanuel Lerman, MD, MSc, CEO and Founder of InflammaSense. "Sepsis hyperimmune and or immunoparalysis states are difficult to detect in real time with existing tools; this program will systematically determine whether continuous, non-invasive ANG monitoring can reliably flag that window early enough to act on it."
About InflammaSense, Inc.
InflammaSense is a pre-revenue medtech company based in La Jolla, California, developing autonomic neurography (ANG) technology for real-time immune monitoring. Its lead indication is sepsis immunoparalysis and sepsis hyperimmune states, paired with matched and targeted therapeutics.
Media Contact:
Imanuel Lerman
InflammaSense, Inc.
[[email protected]] | [619-786-7202]
SOURCE InflammaSense
Share this article
Original Summary
<p>Company will measure autonomic and inflammatory signatures in up to 200 critically ill patients using its VITALx-patch wearable sensor and ARC cascade-endotyping classifier LA JOLLA, Calif., Oct. 7, 2026 /PRNewswire/ -- InflammaSense, Inc., a pre-revenue medtech company developing...</p>
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "InflammaSense Joins $38M ARPA-H Program to Track Sepsis in ICUs", "body_html": "<p><strong>La Jolla, Calif. -- [CURRENT_DATE] --</strong> InflammaSense, Inc. has been selected as a subaward performer on a federal program worth up to $38 million aimed at reprogramming the immune response in critically ill patients, the pre-revenue medtech company announced.</p><h5>ARPA-H taps InflammaSense for $38 million CIRCLE initiative</h5><p>The company joins the Advanced Research Projects Agency for Health's CIRCLE program -- Critical Illness Immunological Reprogramming and Control Point Learning Engine -- as a subaward performer under prime awardee the University of Vermont. InflammaSense will work alongside UVM researcher Gary An on the program's ReSCUED effort.</p><h5>Sepsis drives a chunk of 4.6 million annual critical-illness cases in the US</h5><p>CIRCLE targets immune dysregulation that triggers organ failure in intensive care units, with sepsis accounting for a substantial share of the roughly 4.6 million Americans who face potentially fatal critical illness each year. The program follows a measure-model-modulate framework: compiling real-time immune and inflammatory data, building patient-specific computational models, and testing interventions at immune control points before organ failure sets in.</p><h5>VITALx-patch will track up to 200 ICU patients across three clinical sites</h5><p>Under the subaward, InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 severely critically ill patients. Data collected will feed the company's Autonomic Research Core (ARC) cascade-endotyping classifier, which stratifies patients by immune trajectory and supports CIRCLE's digital-twin modeling of critical illness.</p><h5>Platform rests on UC San Diego-owned neural-signal IP</h5><p>InflammaSense's underlying technology is built on UC San Diego-owned intellectual property covering neural detection of immune responses through cervical Autonomic Neurography, measured via ventral cervical or anterior neck magnetoneurography and electroneurography.</p><p>\"CIRCLE gives us a path to validate ANG at scale in the population it was designed to serve,\" said Imanuel Lerman, MD, MSc, CEO and Founder of InflammaSense. \"Sepsis hyperimmune and or immunoparalysis states are difficult to detect in real time with existing tools; this program will systematically determine whether continuous, non-invasive ANG monitoring can reliably flag that window early enough to act on it.\"</p><p>InflammaSense's lead indication is sepsis immunoparalysis and sepsis hyperimmune states, paired with matched and targeted therapeutics.</p>", "meta_description": "InflammaSense joins ARPA-H's $38M CIRCLE program to deploy its VITALx-patch wearable sensor in up to 200 critically ill ICU patients.", "seo_keywords": "InflammaSense, ARPA-H, CIRCLE program, sepsis, VITALx-patch, autonomic neurography, ICU monitoring, critical illness", "companies": ["InflammaSense", "University of Vermont", "UC San Diego"], "industries": ["Healthcare & Biotech"], "markets_regions": ["United States", "North America"], "news_type": ["grant_award", "research_collaboration"], "products": ["VITALx-patch"], "themes": ["clinical_research", "digital_health", "sepsis_detection"], "events": ["ARPA-H CIRCLE Program"], "cta_text": "Learn more about InflammaSense's ARPA-H CIRCLE subaward and its VITALx-patch wearable sensor technology.", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
8f8e362fff285445ffaca1c8f9c05b8e
